{"title":"Anti diabetic activity of the stem bark extract and fractions of Faidherbia albida Del. (Mimosaceae) in murine model","authors":"A. J. Kashimawo, J. Kolawole, J. Kemelayefa","doi":"10.9790/3008-1204022630","DOIUrl":null,"url":null,"abstract":"Background: In our continued search for potent anti-diabetic compound(s) from plants and natural sources, we tested crude extract and fractions of the stem bark of Faidherbia albida a plant traditional used in the management of diabetes mellitus in Northern Nigeria, on alloxan induced diabetic rats to obtain the most active fraction. Space and Duration of Study: The study was conducted between November 2016-March 2017 using laboratories of Departments of Pharmaceutical Chemistry and Department of Pharmacology of Niger Delta University, Wilberforce Island, Amassoma, Bayelsa State, Nigeria. Methodology: Twenty five rats weighing between 150-200g were made diabetic with alloxan injected peritonialy. They were divided into five groups of five rats each. A sixth group of five normal fats were used for the study. They were treated with F.albida crude extract and fractions as follows; Group 1-crude extract 200mg/kg, Group 2ethylacetate fraction 50mg/kg, Group 3Butanol fraction 50mg/kg, Group 4Glibenclamide 5mg/ kg, Group 5untreated diabetic rats, Group 6Normal rats. Treatment continued for 28 days with blood glucose and weight check weekly. Animals were sacrificed and blood samples collected for biochemical parameters. Results: The blood glucose level of the group treated with ethylacetate was lowered to 142mg/dl which compares favourably with the group treated with glibenclamide (112mg/dl) as opposed to the diabetic untreated group (380mg/dl) at the end of four weeks of treatment. Ethylacetate fraction treated rats showed the least percentage weight loss while there is a significant weight loss (= 0.05) in the diabetic rats Conclusion: Ethylacetate fraction of F.albida showed remarkable effect on blood glucose level and reduced the weight loss in diabetic rats and thus more promising to be further evaluated for bioactive substances.","PeriodicalId":14548,"journal":{"name":"IOSR Journal of Pharmacy and Biological Sciences","volume":"12 1","pages":"26-30"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IOSR Journal of Pharmacy and Biological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9790/3008-1204022630","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Background: In our continued search for potent anti-diabetic compound(s) from plants and natural sources, we tested crude extract and fractions of the stem bark of Faidherbia albida a plant traditional used in the management of diabetes mellitus in Northern Nigeria, on alloxan induced diabetic rats to obtain the most active fraction. Space and Duration of Study: The study was conducted between November 2016-March 2017 using laboratories of Departments of Pharmaceutical Chemistry and Department of Pharmacology of Niger Delta University, Wilberforce Island, Amassoma, Bayelsa State, Nigeria. Methodology: Twenty five rats weighing between 150-200g were made diabetic with alloxan injected peritonialy. They were divided into five groups of five rats each. A sixth group of five normal fats were used for the study. They were treated with F.albida crude extract and fractions as follows; Group 1-crude extract 200mg/kg, Group 2ethylacetate fraction 50mg/kg, Group 3Butanol fraction 50mg/kg, Group 4Glibenclamide 5mg/ kg, Group 5untreated diabetic rats, Group 6Normal rats. Treatment continued for 28 days with blood glucose and weight check weekly. Animals were sacrificed and blood samples collected for biochemical parameters. Results: The blood glucose level of the group treated with ethylacetate was lowered to 142mg/dl which compares favourably with the group treated with glibenclamide (112mg/dl) as opposed to the diabetic untreated group (380mg/dl) at the end of four weeks of treatment. Ethylacetate fraction treated rats showed the least percentage weight loss while there is a significant weight loss (= 0.05) in the diabetic rats Conclusion: Ethylacetate fraction of F.albida showed remarkable effect on blood glucose level and reduced the weight loss in diabetic rats and thus more promising to be further evaluated for bioactive substances.